Spots Global Cancer Trial Database for Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 2 Study of Association Gemcitabine-Cisplatin to Treat Penis Epidermoid Carcinoma
Official Title: Phase 2 Study for Treatment of Penis Epidermoid Carcinoma Loco-regionally Advanced or Metastatic by Association Gemcitabine-Cisplatin
Study ID: NCT00210041
Conditions
Study Description
Brief Summary: The purpose of this study is to determine whether association Gemcitabine-Cisplatin is effective in the treatment of penis epidermoid carcinoma loco-regionally advanced or metastatic.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Locations
Centre Paul Papin, Angers, , France
Institut Bergonie, Bordeaux, , France
Centre François Baclesse, Caen, , France
CHU Grenoble, Grenoble, , France
Centre Léon Bérard, Lyon, , France
Institut Paoli Calmette, Marseille, , France
Institut Val d'aurelle, Montpellier, , France
Institut Curie, Paris, , France
Centre Eugène Marquis, Rennes, , France
Centre Médico-Chirurgical Foch, Suresnes, , France
Institut Claudius Regaud, Toulouse, , France
Contact Details
Name: Christine Chevreau, Doctor
Affiliation: Institut Claudius Regaud
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
